立体定向消融放疗用于延迟寡转移性肾细胞癌全身治疗
该单中心回顾性研究纳入47例初治寡转移性肾细胞癌患者,评估一线立体定向消融放疗(SAbR)的疗效与安全性。结果显示2年局部控制率91.5%,无≥3级毒性,首次SAbR后中位无全身治疗生存期15.2个月,且不影响后续一线全身治疗疗效。
要点
- SAbR对初治寡转移性肾细胞癌局部控制率高且安全性好
- SAbR可延迟全身治疗启动,中位无全身治疗生存期15.2个月
- SAbR后启动的一线全身治疗 duration 似乎不受影响
核心结论
- SAbR是经选择的寡转移性肾细胞癌患者的有效且安全治疗,可提供超过一年的无全身治疗疾病控制,且似乎不影响后续一线全身治疗的疗效。
研究设计与样本
- 回顾性分析2007至2017年UT Southwestern肾癌项目中接受一线根治性意图SAbR的转移性肾细胞癌患者,共47例,88个转移灶,11例接受超过1疗程SAbR。
主要发现
- 2年局部控制率为91.5%,无报告≥3级毒性。
- 中位随访30个月(四分位距13.7-40.9),首次SAbR后中位无全身治疗生存期为15.2个月(95%CI 8.8-40.1)。
- SAbR后最常启动的全身治疗为帕唑帕尼(60.7%)和舒尼替尼(14.3%)。
- SAbR后1年和2年总生存率分别为93.1%(95%CI 80.1-97.7)和84.8%(95%CI 69.1-92.9),中位总生存未达到。
关键数值与推荐
- 2年局部控制率91.5%,无≥3级毒性。
- 中位无全身治疗生存期15.2个月(95%CI 8.8-40.1)。
- 1年总生存率93.1%(95%CI 80.1-97.7),2年总生存率84.8%(95%CI 69.1-92.9)。
临床怎么用
- 对经选择的初治寡转移性肾细胞癌患者,可考虑一线SAbR以延迟全身治疗启动。
- SAbR后启动一线全身治疗时,其疗效似乎不受先前SAbR影响。
局限性
- 回顾性单中心研究,样本量47例,结果需前瞻性2期试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic ablative radiotherapy (SAbR) is a promising alternative for selected patients with renal cell carcinoma (RCC) with oligometastasis. The objective of this study was to evaluate the potential of SAbR for longitudinal control in patients with persistently oligometastatic RCC. We report the impact of SAbR on tumor control rates as well as its tolerability in systemic therapy-naïve patients with oligometastatic disease (without brain metastases) and assess the effect of SAbR on subsequent first line systemic therapy by comparison to historical controls. METHODS AND MATERIALS: We reviewed patients with metastatic RCC treated with front-line SAbR with a curative intent from 2007 to 2017 at UT Southwestern Kidney Cancer Program. We analyzed local control rates (LCR), toxicity, freedom from systemic therapy (FST), type and duration of first-line systemic therapy, and overall survival (OS). Cox regression and Kaplan-Meier analyses were used. RESULTS: We identified 47 patients with oligometastatic RCC treated with SAbR to 88 metastases; 11 patients had more than 1 SAbR course. The local control rate was 91.5% at 2 years with no reported grade ≥3 toxicity. With a median follow-up of 30 months (interquartile range, 13.7-40.9), median FST from first SAbR was 15.2 months (95% confidence interval [CI], 8.8-40.1). The most common systemic therapies initiated after SAbR were pazopanib (60.7%) and sunitinib (14.3%). The duration of first line systemic therapy appeared unaffected by SAbR. Improved FST was observed in patients with metachronous disease (hazard ratio, 2.67; P = .02), solitary metastasis (HR, 2.26; P = .05), and non-bone metastasis (HR, 2.21; P = .04). One-year and 2-year OS after SAbR were 93.1% (95% CI, 80.1-97.7) and 84.8% (95% CI, 69.1-92.9), respectively. Median OS was not reached. CONCLUSIONS: SAbR is an effective and safe treatment for selected patients with oligometastatic RCC, can provide longitudinal disease control without systemic therapy for over a year, and does not appear to adversely affect the effectiveness of first-line systemic therapy once initiated. Prospective validation of these findings is being sought through a phase 2 trial.
引用
- Zhang Y, Schoenhals J, Christie A, et al. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer. Int J Radiat Oncol Biol Phys. 2019. PMID: 31377159. doi:10.1016/j.ijrobp.2019.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。